Biogen flags Q2 and Q3 2026 charges tied to licensing and milestone deals

Biogen filed an 8-K on July 1, 2026 disclosing preliminary estimates for charges tied to acquired in-process research and development, upfront, and milestone expense.

For the second quarter of 2026, the company said it expects its GAAP and non-GAAP results to include acquired in-process research and development, upfront and milestone expense of approximately $164 million on a pre-tax basis.¹ Biogen said this charge is expected to reduce GAAP and non-GAAP net income per diluted share for the quarter by about $0.95 per share.¹

Looking ahead, Biogen said it expects a larger charge in the third quarter of 2026, ranging from approximately $290 million to $320 million, related to potential milestones and transactions that have not yet closed.¹ That estimate is projected to cut third-quarter earnings per share by approximately $1.75 to $1.95 per share.¹

The company explained that this expense category covers costs tied to collaboration and license agreements, including upfront and milestone payments, and in some cases premiums on equity securities and asset acquisitions related to in-process R&D.¹ Biogen noted that it does not typically forecast these figures in advance because of uncertainty around whether, how large, and when such deals will occur.¹

The filing cautions that second-quarter 2026 results have not been finalized and remain subject to closing procedures, so final figures could differ from these preliminary estimates.¹ The 8-K does not name the specific programs, partners, or products tied to these charges, nor does it include other financial or pipeline details.